ADC Therapeutics Triggers Second Target-Specific License to Synaffix ADC Platform under Existing Agreement


Synaffix BV announced today that ADC Therapeutics has triggered a second target-specific license under their Commercial License Agreement dated October 2016, to develop an antibody-drug conjugate (ADC) using Synaffix’s proprietary site-specific antibody-drug conjugation technology. As part of the original agreement, ADC Therapeutics retains an option to take a limited number of additional singletarget licenses for their potential future programs.

“We are delighted that ADC Therapeutics has elected to incorporate Synaffix technology into a
second development program,” said Synaffix CSO, Prof. Floris van Delft, who added, “Our
accomplishments to prepare the components associated with our site-specific technology for
the first cGMP ADC batches will undoubtedly benefit this second program and any future
development programs that are based on Synaffix’s technology. We look forward to an
increasingly close collaboration with the ADC Therapeutics’ team as these compounds advance
through the next stages of development and into the clinic.”

Synaffix is eligible to receive upfront, milestone and royalty payments on a per-target basis.

About Synaffix Platform Site-Specific Antibody-Drug Conjugation Technology
The growing experience of Synaffix and its collaboration partners continues to confirm the
ability of our platform technology to consistently generate ADCs that are more effective and better tolerated when compared to three major clinical-stage ADC conjugation technologies. The proprietary technology platform of Synaffix is comprised of GlycoConnect™, the site-specific and stable antibody conjugation technology that involves proprietary enzymes and metal-free click conjugation components, and HydraSpace™, the ADC-enhancing spacer technology.

GlycoConnect™ was shown to be capable of significantly enhancing the therapeutic index of an
ADC on its own. The highly polar properties of HydraSpace™ improve the solubility and stability of the payload and the resulting ADC product, thus enhancing further the therapeutic index of the ADC.

Both technologies have demonstrated compatibility with all ADC payload classes and all IgG
isotypes and can be applied directly to an existing antibody without any DNA and or protein

About Synaffix BV
Synaffix BV is a biotechnology company that enables highly competitive antibody-drug
conjugate (ADC) product candidates using its site-specific ADC technology platform.

Granted patents covering Synaffix’ technology provide end-to-end protection of the
technology itself as well as resulting products through at least 2035.

Synaffix is backed by a top tier, life science-focused investor syndicate including Aravis,
BioGeneration Ventures, BOM Capital and M Ventures, the strategic corporate venture
capital fund of Merck KGaA, Darmstadt, Germany.

For more information, please visit the website at

Synaffix BV Contact
Anthony DeBoer
Director, Business Development